. 2021 Dec 17;12:799666. doi: 10.3389/fimmu.2021.799666

Table 1.

Published cases of patients with immune checkpoint inhibitor-induced celiac disease (ICI-CeD).

Sex, Age	ICI Name	Antibody	Endoscopic findings	Treatment	Ref.
M, 62 years old	Ipi	tTG-IgA +	Crypt apoptosis	Corticosteroid (prednisone)	Gentile et al.
		Anti-gliadin +	Crypt distortion	Infliximab
		Anti-endomysial –	Intraepithelial lymphocytosis	GFD
W, 63 years old	Pembro	tTG-IgA –	Villous blunting	GFD only	Sethi et al.
W, 63 years old	Pembro	Anti-gliadin +	Crypt hyperplasia	GFD only	Sethi et al.
W, 74 years old	Nivo	tTG-IgA +	Villous atrophy	GFD	Alsaadi et al.
	Ipi		Mucosal erosions	Corticosteroid (budesonide)
			Inflammation in lamina propria
			Intraepithelial lymphocytosis
M, 79 years old	Pembro	tTG-IgA +	Villous atrophy	GFD (lack of adherence)	Arnouck et al.
M, 79 years old	Pembro	Anti-gliadin +	Lamina propria expansion, intraepithelial lymphocytes	Steroid (hydrocortisone)	Arnouck et al.
8 patients:	5 anti PD(L)1	tTG IgA: 8+/8	Only 6 of 8:	GFD: 7/8:	Badran et al.
2 W, 6 M	1 anti-CTLA4		inflammation, mucosal atrophy, mucosal ulcers or erosions (2/6), villous blunting (5/6), increased IELs (4/6), LP cellularity (6/6), surface erosion/ulceration (5/6)	- GFD alone: 5/8
From 44 to 73 years old	2 combined			- GFD + steroid: 2/8
From 44 to 73 years old	2 combined			Steroid + infliximab: 1/8

GFD, gluten-free diet, ICI, immune checkpoint inhibitor; IELs, intraepithelial lymphocytes; Ipi, Ipilimumab; LP, lamina propria, M, man; Nivo, Nivolumab, Pembo, pembrolizumab, PPI, proton pump inhibitors; tTG-IgA, tissue transglutaminase IgA antibodies; W, woman.